AmerisourceBergen posts 13.7% revenue increase for fiscal 2015

VALLEY FORGE, Pa. — AmerisourceBergen on Thursday reported $136 billion in revenue for its fiscal year 2015 ended Sept. 30, representing an increase of 13.7%. Adjusted diluted earnings per share from continuing operations were $4.96, an increase of 24.9% over the prior fiscal year.  

 

“Our strong performance in the September quarter and excellent results for the fiscal year put us in position to continue to meet our long-term strategic and financial objectives in the years ahead,” stated Steven Collis, AmerisourceBergen president and CEO. “Over the course of fiscal 2015, we made a strategic acquisition of MWI Veterinary Supply and earlier this month announced a definitive agreement to acquire PharMEDium Healthcare Holdings. Both of these acquisitions strengthen our position in the pharmaceutical supply channel, and enhance our ability to grow in the future.”

 

For the fourth quarter of fiscal 2015, revenue was $35.5 billion, up 12.3%, reflecting an 8% increase in AmerisourceBergen Drug Corporation revenue, and a 24% increase in AmerisourceBergen Specialty Group revenue. Pharmaceutical Distribution revenues were $34 billion, an increase of 10% compared to the same quarter in the prior year. 

 

ABDC revenues increased 8%, due primarily to the onboarding of the Walgreens Boots Alliance generic pharmaceuticals business, and solid organic sales growth from independent pharmacy, alternate site and health systems customers. ABSG revenues increased 24%, which was driven by strong performance in AmerisourceBergen's blood products, vaccine and physician office distribution businesses, the impact of manufacturer shifts of certain oncology products from full line distribution to specialty distribution, and an increase in sales to community oncology practices.